Amgen announced a plan to reduce its workforce by 12-15% (up to a maximum of 2,900 redundancies) as part of a refocusing of resources on the development of new drugs (last year the US group acquired Onyx Pharmaceuticals for $10.4 billion to buy Kyprolis, a drug for the treatment of multiple myeloma). The redundancy announcement came alongside second-quarter results marked by 23% earnings progressing to $1.55 billion, or $2.01 per share. Adjusted EPS was $2.37, while 11% revenues grew to $5.18 billion. Thomson Reuters analysts estimated EPS on average at $2.07 on $4.9 billion in revenue. The Amgen title which gained 0.54% on Wall Street on Tuesday, trading was up more than 3% in pre-market on the Nasdaq.
Amgen Adjusted Quarterly Earnings Above Expectations
Amgen: agreement for the acquisition of Biovex Group for 1 billion dollars
Robert A. Bradway he is Chairman, Chief Executive Officer, Chairman of the Executive Committee, etc. Of Amgen Inc.. During 2013 he received a total fee of $13,649,807 equal to € 10.201.497 ($ 1.34 gearbox)
TO
